Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health

NEW YORK--(BUSINESS WIRE)-- #ColgatePalmolive--Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization's work on oral health. The four-year funding commitment will help expand oral health education, support integration of oral health into national health systems, and raise awareness of oral health as a public health priority. This initiative builds on Colgate's commitment to providing communities with oral health education and resources. Th.

Business Wire • Jan 20, 2026

3 “Forever Stocks” to Hold When the Market Won't Sit Still

With so much volatility in the market, it's a good time for investors to consider stocks that they can hold for the long haul. These compounders don't have to make up a large part of your portfolio, but they're good stocks to have for investors who like to step away from their screens.

MarketBeat • Jan 19, 2026

Colgate-Palmolive Webcasts 2025 Fourth Quarter & Full Year Earnings Conference Call January 30, 2026 – 8:30 a.m. ET

NEW YORK--(BUSINESS WIRE)--Colgate-Palmolive Company (NYSE:CL) will provide a live webcast of its 2025 fourth quarter and full year earnings conference call on Friday, January 30, 2026, at 8:30 a.m. ET. The call will be hosted by Chairman, President and CEO, Noel Wallace, Chief Financial Officer, Stan Sutula, and Chief Investor Relations Officer and EVP, M&A, John Faucher. Investors may access the earnings press release, prepared materials and the live audio webcast on Colgate's website at.

Business Wire • Jan 16, 2026

Is Colgate's Cost Discipline Enough in a Softer Demand Cycle?

CL is leaning on productivity, AI and cost discipline to offset input inflation and protect margins amid uneven demand.

Zacks Investment Research • Jan 13, 2026

This Consumer-Products Giant's Stock Is a Wall Street Top Pick for 2026

Morgan Stanley analysts named a consumer products giant known for its toothpaste one of their top picks for the year.

Investopedia • Jan 8, 2026

Colgate-Palmolive: The Pullback Makes This Dividend King More Attractive

Colgate-Palmolive is rated a Buy, trading at an attractive valuation after a 30% pullback from its peak, supported by strong brands, resilient financials, and Dividend King status. CL maintains robust free cash flow, a 2.65% dividend yield, a renewed $5B buyback program with a manageable 53.5% dividend payout ratio, and a solid balance sheet. New guidance reflects 1–2% organic sales growth and flat margins, impacted by private label pet food exit, but long-term strategy remains intact.

Seeking Alpha • Jan 7, 2026

Calls of the Day: Disney, Colgate-Palmolive, First Solar, Toll Brothers, D.R. Horton and Amphenol

The Investment Committee debate the latest Calls of the Day.

CNBC Television • Jan 7, 2026

ACI or CL: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Albertsons Companies, Inc. (ACI) or Colgate-Palmolive (CL). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jan 6, 2026

My Dividend Stock Portfolio: New November Dividend Record - 100 Holdings With 12 Buys

I trimmed positions in NVDA and AMD due to valuation concerns and overexposure, favoring BDCs like ARCC, OBDC, and HTGC for yield. November dividend income reached a record $653, up 5% Y/Y, with BDCs now comprising 33% of total dividends despite potential sector-wide dividend cuts. My 2025 target is $11,000 in annual net dividends (8% growth), with flexibility to raise capital for real estate or travel if opportunities arise.

Seeking Alpha • Jan 5, 2026

Colgate-Palmolive: Consistent Long-Term Execution Makes It Attractive

Colgate-Palmolive (CL) is a Dividend King with strong dividend safety, high margins, and consistent long-term execution, currently trading at a reasonable 21.6x earnings. CL's science-based innovation and focus on high-growth categories and incremental product improvements, reinforcing its wide moat and market share, especially in oral care. Despite reduced guidance and sector headwinds, CL remains undervalued with a fair value estimate of $84.18 versus a ~$79 share price, supporting a buy rating.

Seeking Alpha • Jan 3, 2026